Key facts
- This page summarizes Yekaterina Chudnovsky's Form 4 filing for Elicio Therapeutics, Inc. (ELTX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2024, 16:30.
Yekaterina Chudnovsky - 28 Jun 2024 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- ELTX
- Reported as of
- 28 Jun 2024
- Net transaction value
- +$7,984,000
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 16:30:42 UTC
- Prior SEC filing
- 21 Jun 2024
- Next SEC filing
- 14 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yekaterina Chudnovsky
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Yekaterina Chudnovsky filed Form 4 for Elicio Therapeutics, Inc. (ELTX) on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 21 Jun 2024.
- Current net transaction value: +$7,984,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELTX
transaction
Derivative
Common Warrants
Purchase
- Transaction value
- $0
- Shares
- +1,600,000
- Change %
- Price
- $0.000000
- Shares after
- 1,600,000
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,600,000
- Exercise price
- $5.00
- Footnotes
- F1, F2
ELTX
transaction
Derivative
Pre-Funded Warrants
Purchase
- Transaction value
- $7,984,000
- Shares
- +1,600,000
- Change %
- Price
- $4.99
- Shares after
- 1,600,000
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,600,000
- Exercise price
- $0.0100
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%.
Footnote F2
The Common Warrants expire on July 1, 2029.
Footnote F3
Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%.
Footnote F4
The Pre-Funded Warrants do not have an expiration date.